PARP1 and serum lipopolysaccharide activity: PJ-34, a PARP-1 inhibitor, may exert its protective effect on intestinal epithelial cells against invasive Salmonella infection by up-regulating IL-6 production, which has anti-inflammatory and cell-protective effects [19], and counteracts some of the injurious effects of sepsis and endotoxemia.